Wang Yutong, Zhang Qianchun, Huang Mengping, Ai Ganggang, Liu Xiaofeng, Zhang Yuqi, Li Ran, Wu Jie
Yan'an Key Laboratory of Green Chemical Energy, Key Laboratory of New Energy & New Functional Materials, National Center for Quality supervision and Inspection of Oil and Gas products (Yan'an), College of Chemistry and Chemical Engineering, Yan'an University, Yan'an, 716000, China.
School of Biology and Chemistry, Key Laboratory for Analytical Science of Food and Environment Pollution of Qianxinan, Xingyi Normal University for Nationalities, Xingyi, 562400, China.
Talanta. 2025 Feb 1;283:127166. doi: 10.1016/j.talanta.2024.127166. Epub 2024 Nov 6.
Stroke ranks as the second leading cause of disability and mortality globally. Biomarker detection represents a promising avenue for predicting disease severity and prognosis. The expression levels of metalloproteinase-9 (MMP-9), neuron-specific enolase (NSE), and N-terminal pro-brain natriuretic peptide (NT-pro BNP) in blood correlate with stroke severity. Hence, monitoring these biomarkers is crucial for stroke diagnosis and management. Point-of-care testing (POCT) offers on-site diagnostic capabilities, with lateral flow immunoassay (LFIA) being the most widely used method currently. However, traditional LFIA sensitivity requires enhancement. This study introduces an ultra-sensitive surface-enhanced Raman scattering-based lateral flow immunoassay (SERS-based LFIA) strip for simultaneous detection of the three stroke biomarkers using SERS immune tags. Bimetallic core-shell structured SERS immune tags leverage the advantages of two metals, ensuring stability and enhancing Raman signals through plasmon resonance. This development of a POCT based on SERS-based LFIA strips offers rapid, sensitive, and multiplex detection of stroke biomarkers. The limits of detection (LODs) for MMP-9, NSE, and NT-pro BNP were 0.00020 ng mL, 0.00016 ng mL, and 0.00012 ng mL, respectively. Furthermore, enzyme-linked immunosorbent assay (ELISA) validated the accuracy of SERS-based LFIA. Clinical sample analysis demonstrated consistency between outcomes obtained by SERS-based LFIA and ELISA. Thus, SERS-based LFIA presents a novel POCT approach for stroke diagnosis.
中风是全球第二大致残和致死原因。生物标志物检测是预测疾病严重程度和预后的一个有前景的途径。血液中金属蛋白酶-9（MMP-9）、神经元特异性烯醇化酶（NSE）和N末端脑钠肽前体（NT-pro BNP）的表达水平与中风严重程度相关。因此，监测这些生物标志物对中风的诊断和管理至关重要。即时检测（POCT）提供现场诊断能力，侧向流动免疫分析（LFIA）是目前使用最广泛的方法。然而，传统的LFIA灵敏度需要提高。本研究引入了一种基于超灵敏表面增强拉曼散射的侧向流动免疫分析（基于SERS的LFIA）试纸条，用于使用SERS免疫标签同时检测三种中风生物标志物。双金属核壳结构的SERS免疫标签利用了两种金属的优势，通过等离子体共振确保稳定性并增强拉曼信号。基于SERS的LFIA试纸条的这种POCT开发提供了对中风生物标志物的快速、灵敏和多重检测。MMP-9、NSE和NT-pro BNP的检测限分别为0.00020 ng/mL、0.00016 ng/mL和0.00012 ng/mL。此外，酶联免疫吸附测定（ELISA）验证了基于SERS的LFIA的准确性。临床样本分析表明，基于SERS的LFIA和ELISA获得的结果具有一致性。因此，基于SERS的LFIA为中风诊断提供了一种新颖的POCT方法。
